Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis : target trial emulation
© 2023. The Author(s)..
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates regarding optimal treatment timing and dosage. It is unclear whether initiating nirmatrelvir/ritonavir immediately after symptom onset would improve clinical outcomes and/or lead to post-treatment viral burden rebound due to inadequate viral clearance during treatment. Here we show that, by emulating a randomized target trial using real-world electronic medical record data from all 87,070 adult users of nirmatrelvir/ritonavir in Hong Kong between 16th March 2022 and 15th January 2023, early initiation of nirmatrelvir/ritonavir treatment (0 to 1 days after symptom onset or diagnosis) significantly reduced the incidence of 28-day all-cause mortality and hospitalization compared to delayed initiation (2 or more days) (absolute risk reduction [ARR]: 1.50% (95% confidence interval 1.17-1.80%); relative risk [RR]: 0.77 (0.73, 0.82)), but may be associated with a significant elevated risk of viral burden rebound (ARR: -1.08% (-1.55%, -0.46%)), although the latter estimates were associated with high uncertainty due to limited sample sizes. As such, patients should continue to initiate nirmatrelvir/ritonavir early after symptom onset or diagnosis to better protect against the more serious outcomes of hospitalization and mortality.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Nature communications - 14(2023), 1 vom: 16. Dez., Seite 8377 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wong, Carlos K H [VerfasserIn] |
---|
Links: |
---|
Themen: |
7R9A5P7H32 |
---|
Anmerkungen: |
Date Completed 19.12.2023 Date Revised 19.12.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-023-43706-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM365948128 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM365948128 | ||
003 | DE-627 | ||
005 | 20231227134518.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231227s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-023-43706-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1232.xml |
035 | |a (DE-627)NLM365948128 | ||
035 | |a (NLM)38104114 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wong, Carlos K H |e verfasserin |4 aut | |
245 | 1 | 0 | |a Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis |b target trial emulation |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.12.2023 | ||
500 | |a Date Revised 19.12.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates regarding optimal treatment timing and dosage. It is unclear whether initiating nirmatrelvir/ritonavir immediately after symptom onset would improve clinical outcomes and/or lead to post-treatment viral burden rebound due to inadequate viral clearance during treatment. Here we show that, by emulating a randomized target trial using real-world electronic medical record data from all 87,070 adult users of nirmatrelvir/ritonavir in Hong Kong between 16th March 2022 and 15th January 2023, early initiation of nirmatrelvir/ritonavir treatment (0 to 1 days after symptom onset or diagnosis) significantly reduced the incidence of 28-day all-cause mortality and hospitalization compared to delayed initiation (2 or more days) (absolute risk reduction [ARR]: 1.50% (95% confidence interval 1.17-1.80%); relative risk [RR]: 0.77 (0.73, 0.82)), but may be associated with a significant elevated risk of viral burden rebound (ARR: -1.08% (-1.55%, -0.46%)), although the latter estimates were associated with high uncertainty due to limited sample sizes. As such, patients should continue to initiate nirmatrelvir/ritonavir early after symptom onset or diagnosis to better protect against the more serious outcomes of hospitalization and mortality | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Lau, Jonathan J |e verfasserin |4 aut | |
700 | 1 | |a Au, Ivan C H |e verfasserin |4 aut | |
700 | 1 | |a Lau, Kristy T K |e verfasserin |4 aut | |
700 | 1 | |a Hung, Ivan F N |e verfasserin |4 aut | |
700 | 1 | |a Peiris, Malik |e verfasserin |4 aut | |
700 | 1 | |a Leung, Gabriel M |e verfasserin |4 aut | |
700 | 1 | |a Wu, Joseph T |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 16. Dez., Seite 8377 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:16 |g month:12 |g pages:8377 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-43706-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 16 |c 12 |h 8377 |